Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Anlon Healthcare IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2013 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 121.03 Cr
Profile
Price Range 86  to  91 per share
Profile
Min Investment ₹91
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are a R&D driven chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates (“Pharma Intermediate”) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (“APIs”) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (“FDF”) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Our products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. Our active pharmaceutical ingredient products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, USP. Read More

Basic Info

Face Value 10 per share

Price 86  to  91 per share

P/E (x) 14.2

Sales( Cr.) 120

PAT( Cr.) 21

EPS 6.4

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Punitkumar R. Rasadia Meet Atulkumar Vachhani Mamata Punitkumar Rasadia

Pre Issue Share Holding 70.26%

Post Issue Share Holding 52.68%

Listing Details:

Listing Price: 9.1

Listing Gain: -900%

Current Price: 13.9

Gain On Issue: 13.9 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Aug 26, 2025
Closing Date Aug 29, 2025
Allotment Sep 01, 2025
Refund Sep 02, 2025
Delivery of Shares Sep 02, 2025
Listing Date Sep 03, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 164 14,924
Retail (Max) 13 2132 194,012
S-HNI (Min) 14 2296 208,936
S-HNI (Max) 67 10988 999,908
B-HNI (Min) 68 11152 1,014,832

Objective of the Issue

1. Funding capital expenditure requirements for expansion of our Manufacturing Facility (“Proposed Expansion”) 2. Full or part repayment and/or prepayment of certain outstanding secured borrowings (term loan) availed by our Company 3. Funding the working capital requirements of our Company 4. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 9975000 10689028 1.1x
NII 1995000 21161412 10.6x
Retail 1330000 62912368 47.3x
EMP 0 0 0x
Total 13300000 94762808 7.1x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Anlon Healthcare Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 57 113 67 120
Other Income 0 0 0 0
Total Income 58 113 67 120
Total Expenditure 52 100 51 88
Operating Profit 6 13 16 33
Interest 4 4 4 4
Depreciation 2 2 2 2
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax -0 7 10 27
Provision for Tax 0 1 0 6
Profit After Tax -0 6 10 21
Adjustments 0 0 0 0
Profit After Adjustments -0 6 10 21
Adjusted Earnings Per Share -0 0.5 0.6 0.5

Anlon Healthcare Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 2 7 21 80
Minority's Interest 0 0 0 0
Borrowings 52 58 54 38
Other Non-Current Liabilities 2 2 3 2
Total Current Liabilities 29 44 50 60
Total Liabilities 85 112 128 181
Fixed Assets 27 26 27 23
Other Non-Current Assets 0 0 0 0
Total Current Assets 58 86 101 158
Total Assets 85 112 128 181

Anlon Healthcare Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 2 1 2
Cash Flow from Operating Activities -2 -3 -3 -23
Cash Flow from Investing Activities -0 -0 -3 3
Cash Flow from Financing Activities 3 2 8 19
Net Cash Inflow / Outflow 1 -1 2 -1
Closing Cash & Cash Equivalent 2 1 2 1

Anlon Healthcare Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) -0.01 0.49 0.6 0.51
CEPS(Rs) 0.14 0.64 0.72 0.56
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) 0.13 0.61 1.31 2.02
Core EBITDA Margin(%) 9.72 11.11 23.59 27.06
EBIT Margin(%) 7.19 9.67 20.92 25.73
Pre Tax Margin(%) -0.19 6.2 14.64 22.35
PAT Margin (%) -0.19 5.16 14.5 17.06
Cash Profit Margin (%) 3.03 6.81 17.34 18.53
ROA(%) -0.13 5.92 8.06 13.27
ROE(%) -6.93 130.37 67.99 40.45
ROCE(%) 6.42 15.42 15.48 24.83
Receivable days 129.68 103.65 226.22 172.55
Inventory Days 170.48 86.75 188.24 139.55
Payable days 128.3 84.16 245.69 96.98
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 1.27 0.72 1.43 0.87
EV/Core EBITDA(x) 12.25 6.39 6 3.21
Net Sales Growth(%) 0 97.54 -41.01 80.65
EBIT Growth(%) 0 165.95 27.55 122.17
PAT Growth(%) 0 5503.9 65.93 112.46
EPS Growth(%) 0 5503.9 24.45 -14.7
Debt/Equity(x) 40.14 9.54 3.86 0.83
Current Ratio(x) 2 1.97 2.01 2.64
Quick Ratio(x) 1.07 1.35 1.18 1.8
Interest Cover(x) 0.97 2.78 3.33 7.63
Total Debt/Mcap(x) 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 79% 28% 0% 0%
Operating Profit CAGR 106% 77% 0% 0%
PAT CAGR 110% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 40% 80% 58% 58%
ROCE Average 25% 19% 16% 16%

Company Contact Information

Anlon Healthcare Ltd.

Amita Chhaganbhai Pragada

+91 281 2562538/39

cs@anloncro.com

101/102, Silvercoin Complex Opp. Crystal Mall Kalawad Road

IPO Lead Manager(s)

Anlon Healthcare Ltd.

Interactive Financial Services Ltd.

Registrar Info

Anlon Healthcare Ltd.

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District, Nanakramguda Hyderabad – 500032 Tel. No. 040 67161500 Fax. No. 040 23001153 E-mail: einward.ris@karvy.com Website: www.karvy.com Toll Free No. of exclusive Call Centre:1-800-345001

040 - 67162222/18003094001

einward.ris@kfintech.com

https://www.kfintech.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!